Skip to Main Content

A systematic search of medical literature pertaining to contraception was performed during November 2007. The search was limited to human subjects and journals in English language and included PubMed, UpToDate®, and the American College of Obstetricians and Gynecologists Practice Bulletin.

Unintended pregnancy is a major public health problem worldwide. The overwhelming evidence that oral contraceptives are effective for reversible birth control has led to their widespread use in preventing pregnancy. Despite the availability of many contraceptive options, unplanned pregnancy rates remain high even in developed countries. The need for effective contraceptive methods with few side effects has led to a myriad of dose options and delivery systems.

Oral contraception pills (OCPs) were first introduced in the United States by the Food and Drug Administration (FDA) in the early 1960s for the control of irregular menses and infertility. Early preparations contained high estrogen and progestin concentrations, which were later found to result in adverse effects including weight gain, acne, and bloating and thus led to a high rate of discontinuation. The risk of cardiovascular events including stroke, myocardial infarction, and pulmonary embolism was not recognized until well after the approval of OCPs.1 Safety concerns and the adverse side effects associated with high dose formulations have led to the development of OCP preparations with low doses of estrogen and progestin. Preparations containing more than 50 mcg of estrogen are no longer marketed in the United States as a result of the increased risk of thrombosis with higher doses. A variety of progestins, in a range of doses, have been developed in an effort to reduce side effects related to cardiovascular risks and also to reduce androgenic effects related to various progestins.2 As a result of improved safety and efficacy, the age limit for OCP use, previously defined as less than 35 years for smokers and less than 40 years for nonsmokers, has recently been lifted by the FDA.3 Currently, OCPs may be considered as an effective option for birth control until menopause in all healthy, nonsmoking women.

Primary care providers are often called upon to recommend contraceptive therapy for birth control. Appropriate use requires a basic knowledge of the pharmacology, indications, contraindications, efficacy, and the noncontraceptive benefits of OCPs. Making a choice of the many therapeutic options requires consideration of the specific progestins, dosing intervals, and delivery systems available for contraception.

A thorough medical, social, and family history of the patient is important prior to the recommendation of hormonal contraception. Absolute and relative contraindication to the use of OCPs should be identified. On review of systems, the physician may identify an opportunity to choose particular hormones that provide potential benefits in addition to contraception (Table 28-1).

Table 28-1. Potential Noncontraceptive Benefits with Oral Contraceptives

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.